Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM, Domene Ochoa S, López-Causapé C, Luque S, Sorlí L, Campillo N, López Montesinos I, Padilla E, Prim N, Angulo-Brunet A, Grau S, Oliver A, Horcajada JP. Montero MM, et al. Among authors: domene ochoa s. Microbiol Spectr. 2021 Sep 3;9(1):e0058521. doi: 10.1128/Spectrum.00585-21. Epub 2021 Jul 28. Microbiol Spectr. 2021. PMID: 34319141 Free PMC article.
Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
Montero MM, Domene Ochoa S, López-Causapé C, VanScoy B, Luque S, Sorlí L, Campillo N, Padilla E, Prim N, Segura C, Pomar V, Rivera A, Grau S, Ambrose PG, Oliver A, Horcajada JP. Montero MM, et al. Among authors: domene ochoa s. J Glob Antimicrob Resist. 2019 Sep;18:37-44. doi: 10.1016/j.jgar.2019.04.012. Epub 2019 May 30. J Glob Antimicrob Resist. 2019. PMID: 31154007
Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an In Vitro Pharmacodynamic Model.
Montero M, Domene Ochoa S, López-Causapé C, VanScoy B, Luque S, Sorlí L, Campillo N, Angulo-Brunet A, Padilla E, Prim N, Pomar V, Rivera A, Grau S, Ambrose PG, Oliver A, Horcajada JP. Montero M, et al. Among authors: domene ochoa s. Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02542-19. doi: 10.1128/AAC.02542-19. Print 2020 Mar 24. Antimicrob Agents Chemother. 2020. PMID: 32041712 Free PMC article.
Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model.
Montero MM, Domene-Ochoa S, López-Causapé C, Luque S, Sorlí L, Campillo N, Padilla E, Prim N, Ferrer-Alapont L, Angulo-Brunet A, Grau S, Oliver A, Horcajada JP. Montero MM, et al. Among authors: domene ochoa s. Sci Rep. 2021 Nov 12;11(1):22178. doi: 10.1038/s41598-021-01784-4. Sci Rep. 2021. PMID: 34773066 Free PMC article.
Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates.
Montero MM, Domene-Ochoa S, López-Causapé C, López-Montesinos I, Luque S, Sorlí L, Campillo N, Padilla E, Prim N, Ferrer Alapont L, Grau S, Oliver A, Horcajada JP. Montero MM, et al. Among authors: domene ochoa s. Microbiol Spectr. 2022 Jun 29;10(3):e0089222. doi: 10.1128/spectrum.00892-22. Epub 2022 Jun 13. Microbiol Spectr. 2022. PMID: 35695526 Free PMC article.
ATP Bioluminescence Assay To Evaluate Antibiotic Combinations against Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa.
Puig-Collderram B, Domene-Ochoa S, Salvà-Comas M, Montero MM, Duran X, González JR, Grau S, Oliver A, Horcajada JP, Padilla E, Segura C, Prim N. Puig-Collderram B, et al. Among authors: domene ochoa s. Microbiol Spectr. 2022 Aug 31;10(4):e0065122. doi: 10.1128/spectrum.00651-22. Epub 2022 Jul 25. Microbiol Spectr. 2022. PMID: 35876574 Free PMC article.
Synergistic efficacy of ceftazidime/avibactam and aztreonam against carbapenemase-producing Pseudomonas aeruginosa: insights from the hollow-fiber infection model.
Montero MM, Domene-Ochoa S, Prim N, Ferola E, López-Causapé C, Echeverria D, Morisaki MFA, Vega-Toribio V, Sorlí L, Luque S, Padilla E, Oliver A, Horcajada JP. Montero MM, et al. Among authors: domene ochoa s. Infect Dis (Lond). 2025 Jan;57(1):81-88. doi: 10.1080/23744235.2024.2396882. Epub 2024 Aug 30. Infect Dis (Lond). 2025. PMID: 39212630 Free article.
Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa: In Vivo and In Vitro Evidence.
Lopez-Montesinos I, Montero MM, Domene-Ochoa S, López-Causapé C, Echeverria D, Sorlí L, Campillo N, Luque S, Padilla E, Prim N, Grau S, Oliver A, Horcajada JP. Lopez-Montesinos I, et al. Among authors: domene ochoa s. Antibiotics (Basel). 2022 Oct 22;11(11):1456. doi: 10.3390/antibiotics11111456. Antibiotics (Basel). 2022. PMID: 36358110 Free PMC article.